Dialectical Behavior Therapy vs Schema Therapy for Patients With Borderline Personality Disorder The BOOTS Multicenter Randomized Clinical Trial

Authors
  • Jet Alberts
  • Marieke Alkema
  • Eliane C.P. Dek
  • Monique Hupkes
  • Chrissy James
  • Annemieke M. Koppeschaar
  • Maria Ploegmakers
  • Rachel J. Schuur
  • Marieke Van Vliet
  • Arnoud Arntz
Publication date July 2026
Journal JAMA Psychiatry
Volume | Issue number 83 | 7
Pages (from-to) 669-681
Organisations
  • Faculty of Social and Behavioural Sciences (FMG) - Psychology Research Institute (PsyRes)
Abstract
IMPORTANCE  Head-to-head comparisons of evidence-based treatments for borderline personality disorder (BPD), including dialectical behavior therapy (DBT) and schema therapy (ST), remain scarce, despite their widely recognized relevance.
OBJECTIVE  To compare the effectiveness of DBT and ST in a multicenter trial among outpatients with BPD. DESIGN, SETTING, AND PARTICIPANTS This 3-year multicenter superiority randomized clinical trial (RCT), part of the BOOTS (Borderline Optimal Treatment Selection) project, was conducted between January 2019 and April 2025. The trial was conducted in 9 Dutch outpatient centers among individuals aged 18 to 65 years with BPD. Assessments were administered by assessors blinded to treatment allocation.
INTERVENTIONS  Participants were randomized to DBT or ST via computerized covariate-adaptive randomization accounting for sex and BPD severity. Both treatments were delivered over 2 years in a combined group-individual format.
MAIN OUTCOMES AND MEASURES  The primary outcome was the rate of change in DSM-5 BPD severity from baseline to 1-year posttreatment follow-up (3 years after baseline), assessed by the Borderline Personality Disorder Severity Index, fifth version (BPDSI-5) total score. Secondary outcomes included DSM-5 BPD criteria, general symptom severity, functioning, quality of life, well-being, sleep problems, and treatment dropout. RESULTS Of 204 participants (172 female [84.3%]; mean [SD] age, 32.21 [9.57] years), 95 (46.6%) received DBT and 109 (53.4%) received ST. Intention-to-treat analysis revealed no significant difference between DBT and ST in reducing BPD severity (P =.27, r = 0.09), with large improvements in both treatments. At 36-month follow-up, the estimated mean difference was -1.09 on the BPDSI-5 (Cohen d = 0.15; 95% CI, -0.17 to 0.47). No significant differences between treatments were observed on any secondary outcome, with marked improvements over time in both treatments. Dropout did not differ significantly (DBT: 34% at 1 year, 52% at 2 years; ST: 29% at 1 year, 46% at 2 years).
CONCLUSIONS AND RELEVANCE  This multicenter RCT found no significant differences in effectiveness between DBT and ST for outpatients with BPD, with substantial improvements across outcomes. Future research is warranted to assess equivalence and to determine which treatment works best for whom and why. Trial Registration: https://onderzoekmetmensen.nl
Document type Article
Language English
Published at
Other links
Permalink to this page
Back